The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...

默克（Merck）周二宣布，其重磅免疫疗法Keytruda与辉瑞（Pfizer）的抗体药物偶联物Padcev联合疗法，在治疗一种膀胱癌方面显示出积极成果。

默克（Merck）、辉瑞（Pfizer）和安斯泰来（Astellas Pharma）联合开发的一种癌症药物组合疗法在一项针对难治性膀胱癌患者的后期研究中达到了关键目标。

Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its ...

Merck trades at a low P/E with strong financials, Keytruda growth, and a solid 3.9% yield, while its pipeline offsets future risks. Read why MRK stock is a buy.

Merck leans on Keytruda growth and pipeline expansion, Palo Alto rides subscription security demand, and Freeport benefits ...

With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory treatment as it faces pressure to diversify beyond its blockbuster cancer drug ...

Merck stock slid after the company’s earnings report failed to ease worries about the impending expiration of the patents ...

Merck is also working on different strategies to drive Keytruda's long-term growth. These include innovative immuno-oncology combinations, including Keytruda with LAG3 and CTLA-4 inhibitors.

Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.